The effect of atorvastatin on patients with multiple sclerosis
Phase 2
- Conditions
- Multiple Sclerosis.Multiple sclerosis (of):generalized
- Registration Number
- IRCT2015071323184N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Informed consent for entering the study and Fill out the form informed consent; MS disease
Exclusion criteria: Side effects of the drug
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cerebellar function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Visual function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Sensory function. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.;Digestive function - bladder. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.
- Secondary Outcome Measures
Name Time Method Sensitivity to drug. Timepoint: Pretreatment / six months after treatment / one year after treatment. Method of measurement: Due to physician's viewpoint.